46
Views
0
CrossRef citations to date
0
Altmetric
Review

Biologic agents in the treatment of colorectal cancer: an update

&
Pages 363-374 | Published online: 13 Oct 2014

References

  • Ferrara N , Davis-SmythT. The biology of vascular endothelial growth factor. Endocr. Rev.18, 4–25 (1997).
  • Kim KJ , LiB, WinerJet al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature362, 841–844 (1993).
  • Kabbinavar F , HurwitzHI, FehrenbacherLet al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol.21, 60–65 (2003).
  • Hurwitz H , FehrenbacherL, NovotnyWet al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med.350, 2335–2342 (2004).
  • Giantonio BJ , CatalanoPJ, MeropolNJet al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol.25, 1539–1544 (2007).
  • Saltz LB , ClarkeS, Diaz-RubioEet al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized Phase III study. J. Clin. Oncol.26, 2013–2019 (2008).
  • Tebutt NC , WilsonK, GebskiVJet al. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. J. Clin. Oncol.28, 3191–3198 (2010).
  • Cunningham D , LangI, MarcuelloEet al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised Phase 3 trial. Lancet Oncol.14, 1077–1085 (2013).
  • Bennouna J , SastreJ, ArnoldDet al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML 18147): a randomised Phase 3 trial. Lancet Oncol.14, 29–37 (2013).
  • Van Cutsem E , TaberneroJ, LakomyRet al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a Phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J. Clin. Oncol.30, 3499–3506 (2012).
  • Goldberg RM , SargentDJ, MortonRFet al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol.22, 23–30 (2004).
  • Grothey A , SugrueMM, PurdieDMet al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J. Clin. Oncol.26, 5326–5334 (2008).
  • Holash J , DavisS, PapadopoulosNet al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc. Natl Acad. Sci. USA99, 11393–11398 (2002).
  • Kim ES , SerurA, HuangJet al. Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc. Natl Acad. Sci. USA99, 11399–11404 (2002).
  • Bach PB , SaltzLB, WittesRE. In cancer care, cost matters. NY Times, 14 October 2012.
  • Neumann J , WehweckL, MaatzSet al. Alterations in the EGFR pathway coincide in colorectal cancer and impact on prognosis. Virchows Arch.463, 509–523 (2013).
  • Cunningham D , HumbletY, SienaSet al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med.351, 337–345 (2004).
  • Sobrero AF , MaurelJ, FehrenbacherLet al. EPIC: Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J. Clin. Oncol.26, 2311–2319 (2008).
  • Karapetis CS , Khambata-FordS, JonkerDJet al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med.359, 1757–1765 (2008).
  • Bokemeyer C , BondarenkoI, HartmannJTet al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann. Oncol.22, 1535–1546 (2011).
  • Van Cutsem E , KohneCH, HitreEet al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med.360, 1408–1417 (2009).
  • Maughan TS , AdamsRA, SmithCGet al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised Phase 3 MRC COIN trial. Lancet377, 2103–2114 (2011).
  • Tveit KM , GurenT, GlimeliusBet al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J. Clin. Oncol.30, 1755–1762 (2012).
  • Van Cutsem E , PeetersM, SienaSet al. Open-label Phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J. Clin. Oncol.25, 1658–1664 (2007).
  • Douillard JY , SienaS, CassidyJet al. Randomized, Phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J. Clin. Oncol.28, 4697–4705 (2010).
  • Peeters M , PriceTJ, CervantesAet al. Randomized Phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J. Clin. Oncol.28, 4706–4713 (2010).
  • Saltz L , HochsterH, RubinMet al. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc. Am. Soc. Clin. Oncol.20, 3a Abstract 7 (2001).
  • Saltz LB , MeropolNJ, LoehrerPJSret al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol.22, 1201–1208 (2004).
  • Khambata-Ford S , GarrettCR, MeropolNJet al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J. Clin. Oncol.25, 3230–3237 (2007).
  • Amado RG , WolfM, PeetersMet al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol.26, 1626–1634 (2008).
  • Saltz LB , LenzHJ, KindlerHLet al. Randomized Phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J. Clin. Oncol.25, 4557–4561 (2007).
  • Tol J , KoopmanM, CatsAet al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N. Engl. J. Med.360, 563–572 (2009).
  • Heinemann V , Fischer von WeikersthalL, DeckerTet al. Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS wild-type metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3). J. Clin. Oncol.31(Suppl.), Abstract LBA3506 (2013).
  • Berlin J , NeubauerM, SwansonPet al. Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing > 10% epidermal growth factor receptor (EGFr). J. Clin. Oncol.24(Suppl. 18S) 3548 (2006).
  • Hecht JR , PatnaikA, BerlinJet al. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer110, 980–988 (2007).
  • De Roock W , ClaesB, BernasconiDet al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol.11, 753–762 (2010).
  • Douillard JY , OlinerKS, SienaSet al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N. Engl. J. Med.369, 1023–1034 (2013).
  • Hecht JR , MitchellE, ChidiacTet al. A randomized Phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J. Clin. Oncol.27, 672–680 (2009).
  • Schwartzberg L , RiveraF, KarthausMet al. PEAK: a randomized, multicenter Phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J. Clin. Oncol.32(21), 2240–2247 (2014).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.